VolitionRx Limited (VNRX) Operating Margin
- Operating margin · 12 months: Value -791.16%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -791.16% | Operating income / revenue. Period ending 2026-06-30. $-19.45M ÷ $2.46M × 100 ≈ -791.16% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -19.45M USD | Operating Income (Loss) |
| Revenue | 2.46M USD | |
| Cost of products and services | (m) | |
| Research and development | 9.41M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-19.45M | $2.46M | (m) | $9.41M | (m) | -791.16% |
| 2026-03-31 | $-21.57M | $2.47M | (m) | $10.33M | (m) | -874.50% |
| 2025-12-31 | $-21.74M | $1.73M | (m) | $10.08M | (m) | -1258.47% |
| 2025-09-30 | $-22.70M | $1.47M | (m) | $10.20M | (m) | -1542.22% |
| 2025-06-30 | $-23.47M | $1.32M | (m) | $11.39M | (m) | -1778.98% |
| 2025-03-31 | $-24.16M | $1.31M | (m) | $12.38M | (m) | -1846.75% |
| 2024-12-31 | $-27.02M | $1.23M | (m) | $14.41M | (m) | -2190.90% |
| 2024-09-30 | $-29.98M | $1.29M | (m) | $16.36M | (m) | -2331.90% |
| 2024-06-30 | $-32.77M | $976.52K | (m) | $17.54M | (m) | -3355.66% |
| 2024-03-31 | $-35.33M | $797.03K | (m) | $19.28M | (m) | -4432.36% |
| 2023-12-31 | $-35.99M | $775.30K | (m) | $19.55M | (m) | -4641.76% |
| 2023-09-30 | $-35.26M | $651.04K | (m) | $18.38M | (m) | -5415.58% |
| 2023-06-30 | $-34.60M | $518.55K | (m) | $18.06M | (m) | -6672.04% |
| 2023-03-31 | $-33.15M | $341.99K | (m) | $15.89M | (m) | -9692.75% |
| 2022-12-31 | $-31.78M | $306.39K | (m) | $14.57M | (m) | -10372.36% |
| 2022-09-30 | $-32.55M | $200.92K | (m) | $16.43M | (m) | -16202.92% |
| 2022-06-30 | $-32.12M | $193.69K | (m) | $14.89M | (m) | -16585.49% |
| 2022-03-31 | $-29.92M | $178.72K | (m) | $15.26M | (m) | -16744.41% |
| 2021-12-31 | $-28.33M | $90.03K | (m) | $15.54M | (m) | -31468.96% |
| 2021-09-30 | $-25.21M | $82.92K | (m) | $15.93M | (m) | -30401.23% |
| 2021-06-30 | $-22.15M | $58.01K | (m) | $14.67M | (m) | -38183.85% |
| 2021-03-31 | $-21.46M | $38.42K | (m) | $14.51M | (m) | -55860.45% |
| 2020-12-31 | $-21.25M | $13.43K | (m) | $14.53M | (m) | -158176.25% |
| 2020-09-30 | $-19.31M | $6.31K | (m) | $13.34M | (m) | -305935.04% |
| 2020-06-30 | $-18.99M | $22.83K | (m) | $12.80M | (m) | -83145.34% |
| 2020-03-31 | $-17.93M | (m) | (m) | $11.78M | (m) | (m) |
| 2019-12-31 | $-16.04M | $17.10K | (m) | $10.36M | (m) | -93840.22% |
| 2019-09-30 | $-16.57M | (m) | (m) | $10.66M | (m) | (m) |
| 2019-06-30 | $-16.80M | (m) | (m) | $10.75M | (m) | (m) |
| 2019-03-31 | $-17.24M | (m) | (m) | $10.96M | (m) | (m) |
| 2018-12-31 | $-17.90M | (m) | (m) | $10.91M | (m) | (m) |
| 2018-09-30 | $-18.03M | (m) | (m) | $11.13M | (m) | (m) |
| 2018-06-30 | $-17.46M | (m) | (m) | $10.53M | (m) | (m) |
| 2018-03-31 | $-16.34M | (m) | (m) | $9.66M | (m) | (m) |
| 2017-12-31 | $-15.05M | (m) | (m) | $8.91M | (m) | (m) |
| 2017-09-30 | $-14.16M | (m) | (m) | $7.43M | (m) | (m) |
| 2017-06-30 | $-13.61M | (m) | (m) | $7.20M | (m) | (m) |
| 2017-03-31 | $-13.12M | (m) | (m) | $7.22M | (m) | (m) |
| 2016-12-31 | $-12.27M | (m) | (m) | $6.84M | (m) | (m) |
| 2016-09-30 | $-11.62M | (m) | (m) | $6.92M | (m) | (m) |
| 2016-06-30 | $-11.11M | (m) | (m) | $6.79M | (m) | (m) |
| 2016-03-31 | $-10.15M | (m) | (m) | $6.35M | (m) | (m) |
| 2015-12-31 | $-10.01M | (m) | (m) | $6.10M | (m) | (m) |
| 2015-09-30 | $-9.22M | (m) | (m) | $5.74M | (m) | (m) |
| 2015-06-30 | $-8.02M | (m) | (m) | $4.95M | (m) | (m) |
| 2015-03-31 | $-7.05M | (m) | (m) | $4.38M | (m) | (m) |
| 2014-12-31 | $-5.94M | $14.79K | (m) | $4.04M | (m) | -40158.37% |
| 2014-09-30 | $-5.75M | (m) | (m) | $3.48M | (m) | (m) |
| 2014-06-30 | $-4.91M | (m) | (m) | $2.93M | (m) | (m) |
| 2014-03-31 | $-4.91M | (m) | (m) | $2.78M | (m) | (m) |
| 2013-12-31 | $-4.58M | (m) | (m) | $2.50M | (m) | (m) |
| 2013-09-30 | $-4.36M | (m) | (m) | $2.90M | (m) | (m) |
| 2013-06-30 | $-4.31M | (m) | (m) | $3.01M | (m) | (m) |
| 2013-03-31 | $-4.19M | (m) | (m) | $2.92M | (m) | (m) |
| 2012-12-31 | $-4.08M | $54.97K | (m) | $2.84M | (m) | -7428.05% |
| 2012-09-30 | (m) | $54.97K | (m) | $2.33M | (m) | (m) |
| 2012-06-30 | (m) | $27.38K | (m) | $1.96M | (m) | (m) |
| 2012-03-31 | (m) | $15.67K | (m) | $1.81M | (m) | (m) |
| 2011-12-31 | (m) | $0.00 | (m) | $1.51M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |